Sudeep Pharma IPO will open for subscription on November 21, 2025 and closes on November 25, 2025. Incorporated in 1989, Sudeep Pharma Limited is a specialised manufacturer of pharmaceutical excipients, food-grade minerals and nutrition ingredients, catering to customers in more than 100 countries.
In this blog, you’ll find all the details about the Sudeep Pharma IPO, including price band, issue size, financials, and risk factors.
Sudeep Pharma IPO Date
The key pointers for the Sudeep Pharma IPO dates are:
- Bidding Opening Date: November 21, 2025
- Bidding Closing Date: November 25, 2025
- Allotment Date: November 26, 2025
- Initiation of Refunds (in case of less or no allotment): November 27, 2025
- Shares Credited to Your Demat Account: November 27, 2025
- IPO Listing Date: November 28, 2025
- Listing on Exchange: BSE and NSE
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Sudeep Pharma IPO Issue Size
Sudeep Pharma IPO valuation, as denoted by the market capitalisation, is targeted at ₹6,697.85 crores. Here are the essential details:
- Sudeep Pharma IPO Price Band: ₹563 to ₹593 per share
- Lot Size: 25 Shares
- Face Value: ₹1 per share
- Total Issue Size and Amount: 1.50 crore shares (aggregating up to ₹895 crores)
- Fresh Issue Size and Amount: 16 lakh shares (aggregating up to ₹95 crores)
- Offer for Sale and Amount: 1.34 crore shares of ₹1 (aggregating up to ₹800 crores)
Sudeep Pharma IPO Proceeds Usage
The offer for sale component of ₹800 crores will be allocated to selling shareholders. The company plans to deploy the fresh issue proceeds of ₹95 crores towards the following objectives:
- Capital expenditure for the acquisition of machinery for the Nandesari Facility I production line – ₹75.81 crores.
- The remaining amount will be used for general corporate purposes.
Sudeep Pharma IPO Reservations
Sudeep Pharma IPO reservations to different investors are:
- For QIBs: Not more than 50% of the Net Offer
- For NIIs: Not less than 15% of the Net Offer
- For Retail Investors: Not less than 35% of the Net Offer
Sudeep Pharma IPO Lot Size
Sudeep Pharma IPO lot size is 25 shares, wherein bidding can be done in multiples. The minimum amount that each category of investor needs to bid in this IPO is:
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 25 | ₹14,825 |
| S-HNI (Min) | 14 | 350 | ₹2,07,550 |
| B-HNI (Min) | 68 | 1,700 | ₹10,08,100 |
Sudeep Pharma IPO Details: Promoter Holding
Sujit Jaysukh Bhayani, Avani Sujit Bhayani, Shanil Sujit Bhayani, Sujeet Jaysukh Bhayani HUF, Riva Resources Private Limited, and Bhayani Family Trust are the promoters of the company.
Sudeep Pharma Ltd: Company Overview
Sudeep Pharma Limited, founded in 1989, makes pharmaceutical excipients, food-grade minerals and specialty nutrition ingredients for customers in more than 100 countries. It runs four manufacturing plants with a total production capacity of 72,246 metric tons, and offers more than 100 products in the pharmaceutical, food, and nutrition industries.
As of June 2025, the company has served over 1,100 customers and has built longstanding relationships with famous brands, including Pfizer, Intas Pharmaceuticals Limited, Mankind Pharma Limited, Merck Group, etc. The company maintains a strong focus on research and development, supported by two R&D facilities and a team of 41 personnel.
The company is one of the largest producers of food-grade iron phosphate, and it is the only Indian firm with both CEP and written confirmation for selling calcium carbonate as an API in the EU. It is also among the first in India to develop liposomal ingredients for better nutrient absorption.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Sudeep Pharma IPO: Financial Performance
Sudeep Pharma Ltd’s key financials for different periods are as follows:
| Particulars (in ₹ Cr) | FY25 | FY24 | YoY Change |
|---|---|---|---|
| Total Income | 511 | 465 | 10% |
| Profit After Tax | 139 | 133 | 4% |
| EBITDA | 199 | 188 | 6% |
| Net Worth | 498 | 359 | 39% |
| Assets | 717 | 514 | 40% |
| Total Borrowing | 135 | 75 | 80% |
| ROE (%) | 28% | 37% | -9% |
| ROCE (%) | 30% | 41% | -11% |
| Net Debt to Equity Ratio (x) | 0.20 | 0.17 | 0.03 |
- Total Income: Total income increased to ₹511 crores in FY25, marking a 10% year-on-year rise and reflecting steady business growth.
- Profit After Tax: Net profit reached ₹139 crores in FY25, up 4% YoY and showing stable profitability.
- EBITDA: EBITDA improved to ₹199 crores in FY25, a 6% year-on-year increase, indicating healthy operating performance.
- Net Worth: Net worth rose sharply to ₹498 crores in FY25, recording a strong 39% YoY growth driven by consistent earnings.
- Assets: Total assets expanded to ₹717 crores in FY25, up 40% year-on-year, supported by ongoing expansion and capacity additions.
- Total Borrowing: Total borrowing increased to ₹135 crores in FY25, an 80% year-on-year jump, reflecting higher funding for growth initiatives.
- Return on Equity: ROE stood at 28% in FY25, down 9 percentage points year-on-year, largely due to a higher equity base.
- Return on Capital Employed: ROCE came in at 30% in FY25, a decline of 11 percentage points year-on-year, impacted by increased capital employed.
- Net Debt-to-Equity: The net debt-to-equity ratio rose to 0.20 in FY25, while still indicating a conservative leverage position.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
Sudeep Pharma IPO Risk Factors
Sudeep Pharma IPO GMP is ₹130 as of November 19, 2025 (at 15:53). It is expected to list at a 21.92% gain at a price of ₹723. However, GMP is not a safe or assured criterion to bid for an IPO. It is important to do your own analysis before investing in any IPO.
Sudeep Pharma IPO is exposed to various risk factors that can eventually affect its business and investors’ perception:
- Customer concentration: The company relies heavily on a small group of clients. Any drop in orders or the loss of a key customer could hurt revenue and cash flow.
- Stringent compliance: Plants are subject to frequent inspections and must meet standards set by bodies such as USFDA, EXCiPACT, FSSC, WHO-GMP, ISO and HACCP. Any lapse in quality or non-compliance could invite regulatory action and damage reputation.
- Operational interruptions: Production and R&D can be disrupted by equipment failures, industrial accidents, regulatory issues, natural disasters or disease outbreaks. Such events could affect operations, financial performance and liquidity.
For all the insights on Sudeep Pharma IPO and detailed expert advice, you can download the SMC ACE App or visit the SMC telegram channels. Take smart decisions and apply for the Sudeep Pharma IPO easily on the SMC ACE Apply by opening free demat account now.
Frequently Asked Questions – FAQs
1. When does the Sudeep Pharma IPO open and list?
Sudeep Pharma IPO opens on November 21, 2025 and closes on November 25, 2025. The basis of allotment is due on November 26, 2025, refunds (if any) and demat credit are expected on November 27, 2025, and the shares are proposed to list on the BSE and NSE on November 28, 2025.
2. What is the Sudeep Pharma IPO price band, lot size and minimum investment?
Sudeep Pharma IPO price band is ₹563 to ₹593 per share. The lot size is 25 shares, so the minimum retail application is 1 lot (25 shares) costing ₹14,825 at the upper price.
3. How big is the Sudeep Pharma issue and what is its structure?
The total issue size of Sudeep Pharma IPO is 1.50 crore shares, aggregating up to ₹895 crores. This comprises a fresh issue of 16 lakh shares (₹95 crores) and an offer for sale of 1.34 crore shares (₹800 crores). As per the reservation rules, not more than 50% of the net offer is for QIBs, not less than 15% is for NIIs, and not less than 35% is for retail investors.
4. How will Sudeep Pharma use the IPO proceeds?
The company plans to spend ₹75.81 crores on buying machinery for the production line at Nandesari Facility I, with the balance earmarked for general corporate purposes.
5. What is the expected listing gain of Sudeep Pharma IPO?
Based on the latest GMP, Sudeep Pharma IPO is expected to list at around a 22% gain at the price of ₹723. However, this can vary based on subscription levels and overall market momentum.
Author: All Content is verified by SMC Global Securities.
WHY SMC
- 20 Lac+ unique clients
- 33+ Years of Serving
- Advance Technical Analysis
- Free Demat Account
